The effects of ticagreloron the improvements of skin flap viability in rats

Objective: Concession and endothelial defect caused skin flap failure by thrombus. Our study aimed to support flap survive by an anticoagulant agent. Materials and Methods: On this study was used 14 Wistar Albino female rats who are separated control (n=7) and ticagrelor (n=7) groups. Dorsal skin flaps were elevated and sutured same incision area. Ticagrelor was infused 20 mg/kg before 24 hour and 10 mg/kg after operation, each 12 hour, 10 days. % 0.9 NaCl infused for control group. After 10 days, flaps were evaluated topographicly and histochemicaly. Results: Flap survival rate on control group % 62,84(43,40-69,83) and on ticagrelor group % 66,77(57,88-72,68) evaluated. Histopathologycal flap necrosis determined 1/3 distal and proximal parts were same but, central 1/3 part of flap on ticagrelor group has less necrosis than control group. That difference was supported statistical (p<0.05). Conclusion: Conclusion of study; Ticagrelor would increase flap viability and we could use ticagrelor as an alternative drug for flap survive.